Evidence map›Paper›PMID 38829466›Full record

ArticleInternational urology and nephrology2024

Serum IgA/C3 ratio: a useful marker of disease activity in patients with IgA nephropathy.

Kazuo Torikoshi, Tomomi Endo, Tatsuo Tsukamoto, Takashi Yasuda, Yoshinari Yasuda, Tetsuya Kawamura, Seiichi Matsuo, Yusuke Suzuki, Eri Muso

Abstract readMulticenter Study
PubMed Publisher
In one paragraph

Article in International urology and nephrology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Kazuo TorikoshiDepartment of Nephrology and Dialysis, Medical Research Institute Kitano Hospital, PIIF Tazuke-Kofukai, 2-4-20 Ohgimachi, Kita-Ku, Osaka, 530-8480, Japan. kktoriy@gmail.com.ORCID http://orcid.org/0009-0005-5574-9208
Tomomi EndoDepartment of Nephrology and Dialysis, Medical Research Institute Kitano Hospital, PIIF Tazuke-Kofukai, 2-4-20 Ohgimachi, Kita-Ku, Osaka, 530-8480, Japan.
Tatsuo TsukamotoDepartment of Nephrology and Dialysis, Medical Research Institute Kitano Hospital, PIIF Tazuke-Kofukai, 2-4-20 Ohgimachi, Kita-Ku, Osaka, 530-8480, Japan.
Takashi YasudaStudy Group of The Nationwide Retrospective Cohort Study in IgAN, Tokyo, Japan.
Yoshinari YasudaStudy Group of The Nationwide Retrospective Cohort Study in IgAN, Tokyo, Japan.
Tetsuya KawamuraStudy Group of The Nationwide Retrospective Cohort Study in IgAN, Tokyo, Japan.
Seiichi MatsuoStudy Group of The Nationwide Retrospective Cohort Study in IgAN, Tokyo, Japan.
Yusuke SuzukiStudy Group of The Nationwide Retrospective Cohort Study in IgAN, Tokyo, Japan.
Eri MusoDepartment of Nephrology and Dialysis, Medical Research Institute Kitano Hospital, PIIF Tazuke-Kofukai, 2-4-20 Ohgimachi, Kita-Ku, Osaka, 530-8480, Japan.

Funding

Ministry of Health, Labour and Welfare H23-intractable-general-033
6 · The paper itself

Abstract

objectiveHigh serum IgA and low serum C3 levels resulting from lectin and alternative pathway activation might be related to IgA nephropathy (IgAN) progression and exacerbation. This study examined whether the serum IgA/C3 ratio can serve as an IgAN progression marker.

methods(1) This nationwide multicenter retrospective study in Japan included 718 patients with biopsy-confirmed IgAN. The patients whose serum creatinine levels at the time of renal biopsy had doubled were defined as having disease progression. (2) Furthermore, to investigate the pathological significance of a reduction in serum IgA/C3 ratio, we reviewed 63 patients whose serum IgA and C3 data at the end of the observation period were obtained.

results(1) A Kaplan-Meier analysis of the patients with IgAN revealed that the group with a high serum IgA/C3 (≥ 3.3) had a significantly worse renal outcome. In a multivariate analysis of eGFR ≥ 60 mL/min per 1.73m

conclusionThe serum IgA/C3 level might reflect the disease activity and be a potent surrogate marker of therapeutic efficacy in patients with IgAN.

Indexed as

BiomarkersComplement C3Disease ProgressionGlomerulonephritis, IGAImmunoglobulin AAdultFemaleGlomerular Filtration RateHumansMaleMiddle AgedProteinuriaRetrospective StudiesTonsillectomyYoung AdultBiomarkersComplement C3Immunoglobulin AIgA nephropathySerum IgA/C3 ratioTonsillectomy

Identifiers

PMID38829466

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.